Water-based insulating paint is expected to replace solvent-based insulating paint!
Innovent announces the completion of Phase 1 clinical study of IBI321 (anti-PD-1/TIGIT bispecific antibody) for the first patient in China
Sansheng Guojian declares the second domestic paragraph of HER2/PD-1 double antibody
Announcement of the Zhanjiang Municipal Market Supervision Administration on the qualification of 231 batches of food (No. 1 of 2021)
Zhang Wenhong: The key to the Nanjing epidemic depends on the follow-up 1-2 weeks of monitoring
The stock futures linkage is advancing vigorously-the performance analysis and outlook of the petroleum and chemical sectors (part 1)
JAMA Neurology: Mild brain trauma should not be underestimated, CT should be reviewed regularly within 1 year
The first class 1 new drug!
Phase 1 clinical results of nebulized new crown vaccine published "The Lancet-Infectious Diseases"
Second-line indications for liver cancer: What is the efficacy of domestic PD-1 when drug O is withdrawn and drug K is approved?
24 new confirmed cases on the 13th, 1 local case in Yunnan
"Mixed" new crown vaccines are more effective, and immunity can be maintained for at least 1 year
Nat Med: Inherited PD-1 deletion can cause tuberculosis and autoimmune diseases
Chen Jianfeng's group collaborated to discover a new mechanism by which different chemokines regulate the binding of integrin α4β7 to HIV-1 virus
Hengrui Medicine Carrelizumab: First PD-1 approved for first-line nasopharyngeal carcinoma indication
1 mg can cause cancer. The test results of aflatoxin, an expired food, are amazing!
Hengrui PD-1 new indication for nasopharyngeal carcinoma will be approved soon
Hengrui Class 1 new drug is close to NDA, what signals have it released
Do you know the story behind the water-based insulating paint?
Diabetes Care: Analysis of Type 1 Diabetes Hospitalized by COVID-19 in Intensive Care Unit, Mechanical Ventilation and Mortality